Navigating T1D Risk Screening: Identifying Ideal Candidates, Understanding Autoantibodies, and Determining Timing for Rescreening

After 1 year of coaching by the AI app or a DPP-associated coach, reductions in weight and HbA1c and increases in physical activity were equal, an outcome with great promise for scalability.

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

Your daily dose of the clinical news you may have missed.

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Hiddo Heerspink, PhD, PharmD.

Topline phase 3 data shows oral GLP-1 cuts HbA1c by 2.1% when added to basal insulin, nearly triple placebo's effect in patients poorly controlled on current therapy.

The sBLA includes data from the phase 3 INHALE-1 study, which showed Afrezza noninferior to MDI insulin. A PDUFA date is set for May 29, 2026.